• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email
    • The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.
    • Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1
    • Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1
    • Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1
    • Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are pioneering the fight against itch, calling on other veterinarians to help America's itchy dogs find cost-effective itch relief and long-lasting solutions.

    GREENFIELD, Ind., June 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today released a new report highlighting the significance of America's Itchy Dogs and the impact itch has on dogs, their owners, and veterinarians. The first-of-its-kind report includes findings from multiple surveys of pet owners, as well as veterinarians, and reveals startling details on how badly dogs around the country are itching for relief and cost-effective, long-lasting solutions. With Zenrelia™ (ilunocitinib tablets) now widely available as a once-daily, cost-effective solution, veterinarians and dog owners have another option to help dogs get back to normal.

    Veterinarians and pet owners are frustrated by itch.

    "There are more itchy dogs out there than you might realize," said Dr. Jennifer Miller, veterinarian and canine dermatology expert at Elanco. "This report shows that nearly 9 in 10 U.S. dogs are 'itchy dogs,' according to their pet owners, experiencing symptoms of itchiness at any point throughout the year. Seasonal allergies make that worse, with more than 8 in 10 dog owners saying that their cities' pollen levels affect their dogs' itch levels. On average, pet owners say they're spending $173 more and using two additional treatments to treat their dogs' itch during allergy season; and they're desperate for a simple, cost-effective solution." 1

    Veterinarians and Dog Owners Alike Are Frustrated by Itch

    Itching is one of the top reasons dogs are brought to the veterinarian, and it's a frustrating issue for both dog owners and veterinarians alike.2 The new report finds that itchy dog owners on average wait 6 weeks after their dog has started showing symptoms of itch to take them to the veterinarian.2 Ninety percent of veterinarians say that itchy dog owners wait too long before bringing their dog, resulting in raw and infected skin and also an irritated dog owner who wants their dog to experience relief quickly.3 If a veterinarian can't scratch that itch quickly, pet owners will find one who can. Nearly 8 in 10 itchy dog owners who have switched veterinarians report switching after 3 visits or less.2 Switching veterinarians isn't the only extreme circumstance that owners of itchy dogs are willing to take – about half of dog owners say having an itchy dog tests their resolve to have a dog at all. Some say they'd be willing to move to a new city if it was going to help their dog's extreme itch.1

    The report shows that a majority of itchy dog owners crave simplicity and long-lasting relief. When it comes to treating an itchy dog, the majority of dog owners want to give one pill a day compared to multiple pills per day.2 In 2024, 75% of dog owners said that they need more affordable options to stop their dogs' itch. 1

    "These findings highlight the critical need for veterinarians to be an ally in the fight against itch and to deliver effective results by the second visit," says Dr. Joya Griffin, veterinarian and board-certified dermatologist at Animal Dermatology Clinic in Louisville. "Itching doesn't just affect the dog; it can have a significant impact on the whole family. Having the right tools is critical for alleviating the itch and discomfort both seasonally and year-around. I've recently started using Zenrelia in my clinic and have seen firsthand how this once-daily, cost-effective treatment can provide much needed relief during allergy season and for refractory patients who suffer year round."

    Dogs should be up to date on vaccinations prior to starting Zenrelia. It's important to read the package insert, including the full Boxed Warning regarding concurrent vaccine administration, or speak with your veterinarian before use.

    The data also revealed there are a lot of emotions tied to an itchy dog – 53%1 of itchy dog owners report feeling judged by someone in their community for having an itchy dog and 75% feel hopeless when their veterinarian is unable to treat their itchy dog.1

    "As a veterinary dermatologist, I've seen the emotional toll having an itchy dog can take on pet owners. Many of my clients have invested significant time and resources on multiple treatment options that often times do not provide relief for their pet," said Dr. Andrew Rosenberg, veterinarian and President of the American College of Veterinary Dermatology (AVCD). "Now with Zenrelia, I have another great tool in my treatment toolbox that allows me to prescribe a simple, cost-effective solution that provides the relief both dogs and their owners have been craving."

    After finding successful treatment for itchy dogs, veterinarians and pet owners have a stronger bond than ever. In fact, 84% of veterinarians say that dog owners are more likely to visit for other issues with their dog and 70% of dog owners refer other dog owners to their office.3

    "I've seen how helping the dog find zen also increases the bond with my clients," said Dr. Tom Lewis, veterinarian and board-certified dermatologist at Dermatology Animals in Gilbert. "Often times, by the time the dog owner gets to me, they're just as frustrated as the dog is. Now, I know I have a treatment option that I can try that gets both dogs and their owners back to zen; that's why I'm encouraging other veterinarians to join us in becoming allies against itch."

    The Highest Human Allergy Cities Have More Itchy Dogs

    For dog owners and veterinarians who live in the highest human allergy cities in the country, they may be seeing more itchy dogs.1,4 In fact, 85% of dogs in the Allergy and Asthma Foundation's top U.S. allergy capitals experience itch during allergy season, compared to 79% of all U.S. dogs.1 

    The deep dive into these cities, also appropriately called "America's Itchiest Cities," highlights some unique differences in each city and state. For example:1

    • Wichita, KS itchy dog owners are more likely than U.S. dog owners to feel financially burdened when they have to go to a veterinarian to treat their itchy dog.
    • New Orleans, LA has the itchiest dogs year-round.
    • Oklahoma City, OK itchy dog owners are on the hunt for the best treatment.
    • Tulsa, OK itchy dog owners feel the financial strain of trying different treatments more than U.S. dog owners in general.
    • Memphis, TN itchy dog owners are doing the most and spending the most, spending a whopping $548 year-round to treat their dogs' itchiness compared to $302 for U.S. dog owners.
    • Little Rock, AR itchy dog owners report fewer visits to their veterinarian but have tried just as many treatments.
    • Raleigh, NC itchy dog owners are the least judgmental of itchiness.
    • Richmond, VA itchy dog owners are going above and beyond, more likely to seek out a specialist.
    • Greenville, SC itchy dog owners are the most likely to feel compassionate when it comes to itch.
    • Greensboro, NC itchy dogs feel the itch even longer with an extended allergy season.

    Dr. Emily Roberson, veterinarian at Animal Hospital of East Davie just outside of Greensboro, NC, says that she's seen a number of itchy dogs this year and has been relieved to have another treatment option. "Here in North Carolina, we're right in the thick of allergy season, and my clinic has seen an influx of itchy dogs. It's truly heartbreaking to see these pets so uncomfortable. That's why I'm thrilled to have Zenrelia as a treatment option to offer these itchy dogs, and their owners, much-needed comfort."

    For additional information, resources, and to learn more about America's Itchy Dogs visit www.ItchyDogs.com.

    *Drs. Griffin, Rosenberg, and Lewis are consultants for Elanco Animal Health.

    ABOUT ELANCO

    Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com. 

    INDICATIONS

    Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age. 

    IMPORTANT SAFETY INFORMATION

    See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia. 

    WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs. 

    © 2025 Elanco or its affiliates: Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

    PM-US-25-1076

    1 Elanco Animal Health. Data on File

    2 Elanco Animal Health. Data on File

    3 Elanco Animal Health. Data on File

    4 *Allergy Capital dog owners / dogs refers to all respondents living in one of the top 10 allergy DMAs: Wichita, KS; New Orleans, LA; Oklahoma City, OK; Tulsa, OK; Memphis, TN; Little Rock, AR; Raleigh, NC; Richmond, VA; Greenville, SC; Greensboro, NC

    Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]

    Media Contact: Season Solorio (765) 316-0233 [email protected]

    America's Itchiest Cities

    Elanco logo (PRNewsfoto/Elanco Animal Health)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-releases-new-report-highlighting-the-significance-of-americas-itchy-dogs-and-the-need-for-itch-relief-302474271.html

    SOURCE Elanco Animal Health

    Get the next $ELAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    12/9/2024$18.00Buy
    UBS
    12/2/2024$14.00Market Perform
    Leerink Partners
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    12/19/2023$17.00Buy
    Jefferies
    12/15/2023$16.00Equal-Weight → Overweight
    Morgan Stanley
    12/7/2023$18.00Outperform
    Exane BNP Paribas
    4/20/2023$14.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $ELAN
    Financials

    Live finance-specific insights

    See more
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau

      4/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement

      GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-pr

      2/4/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      7/8/24 4:32:39 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/13/24 2:08:55 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/12/24 4:01:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      6/3/25 5:33:45 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Modi Rajeev A.

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      6/3/25 5:32:53 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/20/25 5:23:15 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

      The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

      6/5/25 7:45:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

      GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

      5/28/25 7:25:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco to Participate in the Upcoming Investor Conferences

      GREENFIELD, Ind., May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Thursday, May 22, Jeff Simmons, president and CEO, will participate in the BNP Paribas 2nd Annual Animal Health Day at 12:00 p.m. ET. On Thursday, May 29, Jeff Simmons, president and CEO, and Todd Young, executive vice president and CFO, will participate in a fireside chat at Stifel 2025 Jaws & Paws Conference at 8:00 a.m. ET. Live audio webcasts will be available in the "Events and Presentations" sec

      5/16/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

      The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

      6/5/25 7:45:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

      GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

      5/28/25 7:25:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Strengthens Board of Directors with Addition of Stacey Ma

      Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

      11/12/24 8:33:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ELAN
    SEC Filings

    See more

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • UBS initiated coverage on Elanco Animal Health with a new price target

      UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00

      12/9/24 7:40:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Elanco Animal Health with a new price target

      Leerink Partners initiated coverage of Elanco Animal Health with a rating of Market Perform and set a new price target of $14.00

      12/2/24 6:55:44 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Elanco Animal Health from Overweight to Equal-Weight and set a new price target of $15.00 from $17.00 previously

      9/19/24 7:41:39 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Elanco Animal Health Incorporated

      SD - Elanco Animal Health Inc (0001739104) (Filer)

      5/30/25 10:00:37 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      5/28/25 7:30:32 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Elanco Animal Health Incorporated

      10-Q - Elanco Animal Health Inc (0001739104) (Filer)

      5/7/25 9:05:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/11/25 5:13:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/7/25 4:21:21 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      8/26/24 5:05:35 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care